Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
Recruiting · NCT06364176 · Registry updated 2025-05-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Recruiting | Phase 2 | 2025-05-02 | NCT06364176 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Kansas Medical Center | 169 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Kansas Medical Center | Kansas City | United States | 240 |